Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

New Protein Identification Product

11 Jan 2019 07:00

RNS Number : 8124M
Microsaic Systems plc
11 January 2019
 

11 January 2019

Microsaic Systems plc

 

("Microsaic" or the "Company")

 

Microsaic announces new protein identification product

 

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, announces the introduction of its new protein identification technology.

 

The Microsaic MiD® ProteinID is a break-through mass identification technique that allows users to verify target proteins throughout the whole bioprocessing value chain. By providing deterministic characterisation for proteins and small molecules at the point of need, the Microsaic MiD® ProteinID offers fast results over a mass range of 50-3,200 m/z, the broadest mass coverage for a small footprint mass spectrometer. Driven by design, the Microsaic MiD® ProteinID is transformational for process analytics, as its abilities as a point-of-need technology are derived from simplicity, and low maintenance which allows for minimal down-time and greater confidence in results.

 

Biologic drugs represented eight out of ten top selling drugs in 2016, with expected revenues in 2019 of c$445Bn. Revenues are c$15Bn from the top eight suppliers of manufacturing equipment into this industry.

Biologic manufacture demands real-time analysis throughout the entire process. The Microsaic MiD® ProteinID provides real time analysis from the raw in-coming goods, to upstream 'in-cell' drug production, and subsequent downstream product purification.

The Microsaic MiD® ProteinID was ranked among the top innovative products of the year by The Analytical Scientist Innovation Awards in December 2018.

 

Glenn Tracey, CEO of Microsaic, commented, "Bringing the power of the centralised laboratory to in-situ bioprocessing line measurements, the Microsaic MiD® ProteinID reduces key bioprocessing analyses from days to minutes. This means that operators can monitor feedstocks, metabolites and target proteins in just one measurement, thus accelerating time-to-market for new biologics development. Mass spectrometry can now offer superlative performance to high value manufacturing industries at the point-of-need, providing much greater insights over ubiquitous optical sensors."

 

 

Enquiries:

 

 

Microsaic Systems plc

Glenn Tracey, CEO

Bevan Metcalf, FD

+44 (0) 1483 751 577

 

N+1 Singer (Nominated Adviser & Broker)

Shaun Dobson / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

+44 (0)20 7496 3000

IFC Advisory Ltd (Financial PR)

Graham Herring

Heather Armstrong

Florence Chandler

+44 (0)20 3934 6630

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company works with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

The Microsaic's compact MiD® MS systems retain the functionality of larger conventional MS systems, while being easier to use by non-specialists, and consume less energy and have lower running costs. For more information, please go to www.microsaic.com.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAURRWRKBAAAAR
Date   Source Headline
24th Nov 20222:00 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
13th Sep 20227:25 amRNSSupply of mass spectroscopy services to DeepVerge
22nd Aug 20227:00 amRNSPartnership with Kingfield Electronics
5th Jul 20224:41 pmRNSSecond Price Monitoring Extn
5th Jul 20224:35 pmRNSPrice Monitoring Extension
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:01 pmRNSPrice Monitoring Extension
4th Jul 20224:43 pmRNSReplacement: Trading Update
1st Jul 20222:09 pmRNSHolding(s) in Company
30th Jun 202212:11 pmRNSResult of AGM
30th Jun 20227:00 amRNSTrading Update
1st Jun 20227:00 amRNSPosting of Annual Report & Notice of AGM
30th May 20227:00 amRNSFinal Results
19th Apr 20227:00 amRNSManufacturing Services Framework Agreement
28th Mar 20227:30 amRNSUpdate on Microsaic's miniaturised technology
15th Mar 20227:00 amRNSBoard Appointment and Strategic Update
8th Mar 20224:35 pmRNSPrice Monitoring Extension
7th Mar 20222:05 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
21st Feb 20221:31 pmRNSHolding(s) in Company
17th Feb 20222:45 pmRNSHolding(s) in Company
16th Feb 202211:06 amRNSSecond Price Monitoring Extn
16th Feb 202211:00 amRNSPrice Monitoring Extension
14th Feb 20227:00 amRNSDirector Dealing, Issue of Equity and TVR
28th Jan 20227:00 amRNSResignation of Chief Executive Officer
12th Jan 20224:43 pmRNSHolding(s) in Company
10th Jan 20223:30 pmRNSInvestor Presentation
10th Jan 20227:00 amRNSTrading Update
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSFurther order from DeepVerge
12th Nov 20217:00 amRNSNew compact screening platform
5th Nov 202110:12 amRNSHolding(s) in Company
27th Oct 20217:00 amRNSLaunch of technology for scaling drug manufacture
22nd Oct 20217:00 amRNSBoard Change
21st Oct 20217:00 amRNSUpdate on DeepVerge Collaboration
28th Sep 20214:30 pmRNSHolding(s) in Company
27th Sep 20217:00 amRNSInterim Results
24th Sep 20217:00 amRNSSigning of agreement to support China operations
22nd Sep 202111:06 amRNSNotice of Results and Investor Presentation
27th Aug 20214:40 pmRNSSecond Price Monitoring Extn
27th Aug 20214:35 pmRNSPrice Monitoring Extension
23rd Aug 20217:00 amRNSDeepVerge Collaboration for Water & Soil Analysis
9th Aug 20217:00 amRNSHeads of Terms signed with manufacturer in China
6th Jul 202111:55 amRNSInvestor Presentation
6th Jul 20217:00 amRNSTrading update for H1 2021
5th Jul 20219:50 amRNSHolding(s) in Company
2nd Jul 20217:00 amRNSDevelopment of real-time monitoring solution
17th Jun 202110:54 amRNSResult of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.